Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Expertise in Travel Health
    • Our Environmental, Social, and Governance (ESG) Commitments
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with major unmet needs Learn More
    • Products
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development Learn More
    • Pipeline
    • Chikungunya – VLA1553
    • Lyme Disease – VLA15
    • Shigella – S4V2
    • Zika – VLA1601
    • Expanded Access Policy
    • Scientific Publications
    • Investigator Initiated Studies
  • Investors
    Investors Learn More
    • Events
    • Corporate Presentations
    • Financial Reports
    • SEC Filings
    • Press Releases
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance and Ethics
    • Regulated Information
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • General Meetings
      • June 26, 2024 Combined General Meeting
      • General Meeting Archive
    • Videos and Webcasts
    • FAQ
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • Our Stories
    • Media Kit
    • Media Contacts
  • Careers
  • EN
  • FR
  • DE
Search

Press Releases

February 11, 2013

VIVALIS SPECIAL AND COMBINED SHAREHOLDERS MEETINGS TO BE HELD MARCH 7, 2013

February 5, 2013

VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH LICENSE WITH THE ITALIAN ANIMAL HEALTH VACCINE COMPANY FATRO

January 28, 2013

Intercell and Vivalis provide update on the progress towards intended merger

January 24, 2013

REGISTRATION OF DOCUMENT E RELATED TO PROPOSED MERGER OF EQUALS BETWEEN VIVALIS AND INTERCELL

January 15, 2013

2013 FINANCIAL CALENDAR VIVALIS SHARES TRANSFERRED TO COMPARTMENT B OF NYSE EURONEXT

December 16, 2012

Proposed Merger of Equals between Vivalis and Intercell Creation of a European Biotech Leader in Vaccines and Antibodies

November 28, 2012

VIVALIS RECEIVES PRIZE FOR INVESTOR RELATIONS

November 26, 2012

VIVALIS ANNOUNCES A NEW REGISTRATION DOSSIER SUBMISSION OF AN EB66® BASED VACCINE FOR MARKET APPROVAL

November 13, 2012

VIVALIS ANNOUNCES A NEW EB66® RESEARCH AGREEMENT FOR THE ASSESSMENT OF MANUFACTURABILITY OF TWO HUMAN VACCINES

November 9, 2012

VIVALIS WINS A 2012 DELOITTE TECHNOLOGY FAST 50 WEST AWARD

  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 59

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Contact
© 2025 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT REJECT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website. Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website. For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you. The information collected through these tracking and performance cookies do not identify any individual visitor.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT